Edge Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Edge Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-200	Closed	-$16K	–	590
2020 Q2	$16K	Hold	200	–	–	﹤0.01%	404
2020 Q1	$9K	Hold	200	–	–	﹤0.01%	410
2019 Q4	$9K	Hold	200	–	–	﹤0.01%	435
2019 Q3	$8K	Hold	200	–	–	﹤0.01%	437
2019 Q2	$13K	Hold	200	–	–	﹤0.01%	392
2019 Q1	$14K	Hold	200	–	–	﹤0.01%	367
2018 Q4	$9K	Hold	200	–	–	﹤0.01%	416
2018 Q3	$15K	Buy	+200	New	+$16.3K	﹤0.01%	399
2018 Q1	–	Sell	-300	Closed	-$13K	–	573
2017 Q4	$13K	Hold	300	–	–	﹤0.01%	350
2017 Q3	$16K	Buy	+300	New	+$17.8K	﹤0.01%	325

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Edge Wealth Management's RARE Position: Q3 2020 in Review

Edge Wealth Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2020, closing a stake of 200 shares — an estimated $16K sold.

Edge Wealth Management first reported a position in RARE in Q3 2017 and held it in 10 quarters. The position peaked at $16K in Q2 2020. 207 funds tracked by Wall St. Rank hold RARE as of Q3 2020.

Edge Wealth Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2020 after selling out during the quarter.
Edge Wealth Management sold 200 Ultragenyx Pharmaceutical shares in Q3 2020, an estimated $16K.
Edge Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q3 2017 and held it in 10 quarters.
Edge Wealth Management's Ultragenyx Pharmaceutical position peaked at $16K in Q2 2020.
207 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2020.

Based on Edge Wealth Management's 13F filing for Q3 2020, filed 21 Oct 2020.